A Study to Test Whether Treatment With BI 770371 in Combination With Pembrolizumab With or Without Cetuximab Helps People With Head and Neck Cancer Compared With Pembrolizumab Alone

NCT06806852 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: BI 770371
DRUG: Pembrolizumab
DRUG: Cetuximab

Sponsor

Boehringer Ingelheim